Participation aux congrès internationaux

ASCO Annual meeting
- May 30th - June 3rd 2014 / Chicago, USA

Constitutive Single Nucleotide Polymorphisms assessment for predicting tolerability and efficacy of triplet hepatic artery infusion and intravenous cetuximab in patients with liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). Lévi F., Karaboué A., Saffroy R., Peyric E., Ducreux M., Smith D., Hebbar H., Innominato P., Pernot S., Carvalho C., Guimbaud R., Focan C., Bouchahda B., Adam R., Etienne M.C., Milano G., Lemoine A., on behalf of ARTBC International.

Four-year survival in patients undergoing liver surgery after neoadjuvant triplet hepatic artery infusion and intravenous cetuximab previously treated unresectable liver metastases from Kras wt colorectal cancer (European trial OPTILIV, NCT00852228). Lévi F., Ducreux M., Smith D., Hebbar H., Lepère C., Focan C., Guimbaud R., Innominato P., Carvalho C., Tumolo S., Truant S., Castaing D., Karaboué A., Boige V., Bouchahda B., Rougier P. and Adam R., on behalf of ARTBC International.

Detection of health-related warning signals through daily telemonitoring of cancer patients on multidrug chemotherapy at home (European Project inCASA).
Arbaud A., Innominato P., Mohammad-Djafari A., Haydar M., Ulusakarya A., Bossevot-Desmaris R., Plessis V., Mocquery M., Bouchoucha D., Beau J., Bouchahda M., Karaboué A., Morère J.F., Fursse J., Caprino M., and Lévi F.

- May 31st -June 4th 2013 / Chicago, USA

Robustness of circadian rest-activity rhythm for predicting efficacy of intravenous cetuximab and hepatic artery infusion of chronomodulated irinotecan, 5-fluorouracil and oxaliplatin for liver metastases from colorectal cancer (Optiliv translational study, NCT00852228). Karaboué A., Innominato P., Bouchahda M., Mocquery M., Bossevot R., Plessis V., Bouchoucha D., Adam R. and Lévi F., for the ARTBC International Chronotherapy Group. J Clin Oncol 31, 2013 (suppl; abstr e20519).

Hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab (Optiliv) after failure on one versus two or three chemotherapy protocols in patients (pts) with unresectable liver metastases from wt KRAS colorectal cancer (European Phase II clinical trial NCT00852228). Ducreux M., Innominato P. F., Hebbar M., Smith D.M., Lepère C., Focan C., Guimbaud R., Carvalho C., Tumolo S., Awad S., Truant S., Castaing D., Karaboué A., De Baere T., Kunstlinger F., Bouchahda M., Boige V., Rougier P., Adam R., Levi F. J Clin Oncol 31, 2013 (suppl; abstr 3599).

Chronomodulated hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin plus intravenous cetuximab (Chrono-Optiliv) in patients with unresectable liver metastases from wt KRAS colorectal cancer after treatment failure (European Phase II trial NCT 00852228). Bouchahda M., Karaboué A., Etienne-Grimaldi M.C., Chatelut E., Innominato P. F., Paintaud G., Ricca L., Vibert E., Ajavon Y., Awad S., Castaing D., Focan C., Milano G., Morere J.F., Adam R., Levi F. J Clin Oncol 31, 2013 (suppl; abstr 3606).

- June 1 - 5th, 2012 / Chicago, USA

First european phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228). Levi F., Ducreux M.l, Hebbar M., Rougier P., Focan C. N. J., Guimbaud R., Carvalho C.., Tumolo S., Innominato P. F., Ajavon Y., Castaing D., De Baere T., Karaboué A., Lepere C., Boige V., Proux L., Adam R., Bouchahda M., On behalf of ARTBC International. J Clin Oncol 30, 2012 (suppl; abstr 3547).

Circadian rest-activity rhythm as a predictor of survival in metastatic colorectal cancer. Spiegel D., Dugué P.A., Innominato P.F., Karaboué A., Dispersyn G., Parganiha A., Giacchetti S., Moreau T., Focan C. N. J., Waterhouse J., Lévi F. J Clin Oncol 30, 2012 (suppl; abstr e14006)

- June 3– 7th, 2011 / Chicago, USA

Pharmacokinetic-pharmacodynamic analysis of hepatic artery infusion of three-drug chronomodulated chemotherapy and intravenous cetuximab in patients with liver metastases from colorectal cancer registered in OPTILIV, a european multicenter phase II trial. F. Levi, A. Karaboué, M. C. Etienne-Grimaldi, E. Chatelut, P. F. Innominato, G. Paintaud, P. oukakos, R. Adam, M. Bouchahda, G. Milano. J Clin Oncol 29: 2011 (suppl; abstr e14134).

Safety and efficacy of neoadjuvant combination of hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab in patients with unresectable liver metastases from colorectal cancer. Interim report from OPTILIV, a european multicenter phase II trial. M. Ducreux, P. Rougier, D. Smith, C. N. J. Focan, P. F. Innominato, M. Bouchahda, Y. Ajavon, D. Castaing, T. De Baere, A. Karaboué, C. Lepere, V. Boige, R. Adam, F. Levi. J Clin Oncol 29: 2011 (suppl; abstr e14102).

- June 4-8th, Chicago, 2010 / Chicago, USA

Optimal control of liver metastases with intravenous cetuximab and hepatic artery infusion of three-drug chemotherapy in patients with liver-only metastases from colorectal cancer. A European multicenter phase II trial. Levi F., Bouchahda M., Ducreux M., Karaboué A., Focan C. N. J., Rougier P., Innominato P., Smith D., Awad S., Adam R. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS198).

- May 30th - June 3rd, 2008 / Chicago, USA

Relevance of circadian coordination for the outcome of cancer patients. Lévi F., Parganiha A., Innominato P.F., Karaboué A., Poncet A., Moreau T., Garufi C., Focan C., Coudert B., and Georg B., for the ARTBC Chronotherapy Group. J Clin Oncol 2008: 26 (15) suppl 15043.

Efficacy and safety of cetuximab given with a simplified, every other week, schedule in advanced colorectal cancer: A multicenter, retrospective study. Bouchahda M., Tabernero J., LIedo G., Levi F., Macarulla T., Karaboue A., Artru P., Castagne V., Bonnet D., Guimbaud R.

Relevance of circadian coordination for the outcome of cancer patients. Lévi F., Parganiha A., Innominato P.F., Karaboué A., Poncet A., Moreau T., Garufi C., Focan C., Coudert B., and Georg B., for the ARTBC Chronotherapy Group. J Clin Oncol 2008: 26 (15), suppl 15043.

- June 1-5th,2007 / Chicago, USA

Relevance of a medicosurgical strategy combining cetuximab and chronomodulated chemotherapy with metastases resection as 3rd line treatment for patients with metastatic colorectal cancer. Karaboue A., Bouchahda M., Adam A., Innominato I., Bralet M.P., Moreau T., Hauteville D., Guettier C., Levi F. J Clin Oncol 2007: 25 (18), suppl 14505.

ASCO Gastrointestinal cancers symposium
- January 24-26th 2013 / San Francisco, USA

Final results of first European phase II trial of intravenous cetuximab and hepatic artery infusion of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colo-rectal cancer after systemic treatment failure (OPTILIV, NCT00852228). Levi F., Boige V., Hebbar M., Smith D.M., Lepère C., Focan C., Guimbaud R., Carvalho C., Tumolo S., Innominato P. F., Ajavon Y., Truant S., Castaing D., De Baere T., Kunstlinger F., Karaboué A., Bouchahda M., Rougier P., Adam R., Ducreux M. J Clin Oncol 30: 2012 (suppl 34; abstr 466).

- January 19 -21st 2012 / San Francisco, USA

Relations between systemic chemotherapy exposure and treatment effects in patients on hepatic artery infusion of chronomodulated triplet and intravenous cetuximab for liver metastases from colorectal cancer. A companion study to OPTILIV european phase II trial. F. Levi, A. Karaboué, M. C. Etienne-Grimaldi, E. Chatelut, P. F. Innominato, G. Paintaud, L. Ricca, R. Adam, C. N. J. Focan, M. Bouchahda, G. Milano.

Circadian robustness as an independent predictor of prolonged progression-free survival and overall survival in 436 patients with metastatic colorectal cancer. Lévi F., Parganiha A., Karaboué A., Innominato P. F., Giacchetti S., Garufi C., Dispersyn G., Focan C. N. J., Iacobelli S., Bjarnason G. A., Moreau T., Dugue P. A., Waterhouse J., ARTBC International Chronotherapy Group. J Clin Oncol 30, 2012 (suppl 4; abstr 464).

- January 20-22th, 2011 / San Francisco, USA

Chemotherapy-induced neutropenia association with survival in metastatic colorectal cancer: schedule-dependency. Innominato P.F., Giacchetti S., Smaaland R., Focan C., Garufi C., Bjarnason G., Iacobelli S., Tumolo S., Karaboué A., Levi F. J Clin Oncol 29: 2011 (suppl 4; abstr 454).

ESMO European cancer congress
- 25 - 29 September 2015 / Austria, Vienna

Use of Early tumor shrinkage to as a predictor forpredict long-term outcome in patients with unresectable liver metastases from wt-KRAS colorectal cancer treated with hepatic artery infusion of Irinotecan, 5-Fluorouracil and Oxaliplatine plus intravenous Cetuximab after failure of one to three systemic protocols (European phase II clinical trial NCT00852228). Bouchahda M, Boige V, Smith D, Karaboué A, Hebbar M, Lepère C, Focan C, Guimbaud R, Innominato P, Awad S, Carvalho C, Tumolo S, Truant S, De Baere T, Castaing D, Rougier P, Morère JF, Ducreux M, Adam R and Lévi F, on behalf of ARTBC International.

- September 28th – October 2nd, 2012 / Vienna, Austria

Robustness of circadian rest-activity rhythm for predicting the antitumor efficacy of intravenous cetuximab and hepatic artery infusion of chronomodulated Irinotecan, 5-Fluorouracil and Oxaliplatin for colorectal cancer liver metastases. An OPTILIV companion study. A. Karaboue, P. Innominato, M. Bouchahda, M. Mocquery, R. Bossevot, V. Plessis, D. Bouchoucha, R. Adam, F. Levi.

- September 29th - October 3rd, 2006 / Istanbul, Turkey

Determinants of cetuximab reversal of resistance to chronomodulated chemotherapy as 4th line treatment of metastatic colorectal cancer. Lévi F., Karaboué A., Bralet M.P., Innominato P., Moreau T., Herelle M.O., Hauteville D., Adam R., Guettier C., Bouchahda M. Ann. Oncol., 2006: 17 (9), suppl 358.

EBRS Annual meeting
- August 18-22nd , 2014 / Munich, Germany

Thoracic surface temperature rhythm as a circadian biomarker for cancer chronotherapy. Roche V. P., Mohamad-Djafari A., Innominato P. F., Karaboué A., Gorbach A. M., Lévi F. A. Chronobiol Int. 2014 Jan 7.

- August 20-26th, 2011 / Oxford, United Kingdom

Concomitant monitoring of skin surface temperature and rest-activity circadian rhythms as biomarkers for cancer chronotherapeutics. Roche V., Scully C., Li X.M., Dulong S., Karaboue A., Innominato P., Gorbach A., Lévi F.

SFC Congrès annuel
- 8-11 Septembre 2010 / La Colle sur Loup, France

Pooled analysis of rest‐activity rhythm as a prognostic factor for progression‐free survival and overall survival in patients with metastatic colorectal cancer. Lévi F., Parganiha A., Dugué P.A., Karaboué A., Innominato P., and Waterhouse J. for the Chronotherapy Group of ARTBC International.

- 19-21 Septembre 2007 / Paris, France

Relation between circadian rest-activity rhythm, quality of life and survival in cancer patients. Parganiha A., Waterhouse J., Karaboue A., Innominato I., Iurisci I., Giacchetti S., Moreau T., Lévi F.

JFHOD
- 21-24 mars 2013 / Paris, France

Efficacité et tolérance de la trithérapie intra-artérielle hépatique combinée au Cetuximab intraveineux chez les patients avec métastases hépatiques de cancer colorectal non résécables et résistant à la chimiothérapie systémique (OPTILIV, NCT00852228). Lévi F., Boige V., Hebbar M., Smith D., Lepère C., Focan C., Guimbaud R., Carvalho C., Tumolo S., Innominato P., Ajavon Y., Truant S., Castaing D., De Baere T., Kunstlinger F., Karaboué A., Bouchahda M., Rougier P., Adam R. et Ducreux M., pour l’ ARTBC Internationale. SNFGE réf : CO. 69.

- 25-28 Mars 2010 / Paris, France

Mutations acquises du gène KRAS dans le développement de métastases d’un cancer colorectal : implications possibles dans le traitement et le pronostic. Bouchahda M., Karaboué A., Saffroy R., Innominato P., Guettier-Bouttier C., Adam R., Gorden L., Lévi F. SNFGE Réf P.402

Schéma simplifié (toutes les 2 semaines) pour le cetuximab dans le cancer colorectal avancé : une analyse rétrospective multicentrique. Bouchahda M., Macarulla T., Liedo G., Lévi F., Elez E., Paule B., Karaboué A., Artru P., Tabernero J., Machover D., Innominato P., Goldschmidt E., Bonnet D., Ducreux M., Castagne V., Guimbaud R. SNFGE Réf 2010.

PROUST Conference
- October 16-18th, 2008 / Torino, Italy

Rest-activity rhythm, a biomarker of the circadian timing system that predicts for toxicity and survival outcomes in cancer patients. Parganiha A., Waterhouse J., Karaboué A., Innominato P., Poncet A., Iurisci I., Giacchetti S., Moreau T., Lévi F.

IAP Annual Meeting
- Sept 16-21st, 2006 / Montreal, Canada

Immunohistochemistry and fluorescent in situ hybridization for Epidermal Growth Factor Receptor in metastatic colorectal carcinomas are not predictive for response to chronomodulated chemotherapy combined with cetuximab. Bralet M.P., Herelle O., Bouchahda M., Karaboué A., Schoevaert D., Levi F., Guettier C.

ICACC
- June 1-5th, 2005 / Antalya, Turkey

Prolonged monitoring of rest-activity rhythm for assessing chemotherapy effects on circadian system. Iurisci I., Beau J., Karaboué A., Giacchetti S., Innominato P., Carnino S., Laskowski P., Richard S., Iacobelli S., Jasmin C., Lévi F.

ACM
- 10-13 Mars 2005 / Aussois, France

Effects of restricted feeding time during rest period on tumor progression. Fujii Y., Carrière J., Innominato P., Iurisci I., Karaboué A., Smaaland R., Li X.M., Filipski E., Shimada H., Lévi F.

Rôle du moment du pic d’une perfusion chronomodulée de chimiothérapie sur sa toxicité chez des patients atteints de cancer colorectal métastatique. Lévi F., Karaboué A., de la Valette V., Baron B., Giacchetti S., Brézault-Bonnet C., Jasmin C.